Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$AKBA: Nuttssssssssssssssssssssss
Whats the deal here...... now $2.80
Someone wanna shed some light on this ???
GO $AKBA
ALKB FDA APPROVED BIO BEAST
AKBA READY FOR 3 BUCKS
AKBA...............................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
AKBA BREAKING above 2.00 bio beast setting up
Wow. After that update somebody finally got this one figured out. It's going 5 to 10 dollars this year. Then, depending on the progress and outcome of the next trial start again August of 2025, we're talking 20 - 30 Dollars or more in 2026 and 27.
AKBA test that 2.50 from a year ago
AKBA....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
akba........................https://stockcharts.com/h-sc/ui?s=akba&p=W&b=5&g=0&id=p86431144783
AKBA.............................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
AKBA.................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
AKBA BEASTING LONG...FDA APPROVED DRUG COMES TO MARKET IN JAN
AKBA BUILDING 1.79 BREAK IS COMING
AKBA BACK IN PLAY UNTIL JAN 2025...FDA COMING
AKBA.....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
AKBA................................https://stockcharts.com/h-sc/ui?s=ARKB&p=W&b=5&g=0&id=p86431144783
AKBA......................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
I believe the current news releases may have answered your question. GLTA
Why do you say we have a gold mine here ?
Toofuzzy
There's no doubt we have a gold mine here, and at some point it will be load up time. Figuring out when is the big question!
https://journey.ct.events/view/a825b116-e5ee-4e76-ad8d-2e9e9116aa21 tomorrows web cast
Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
I'm in at 33 cents so I'm not going anywhere, just gonna let it ride wherever it goes
Thanks, I’m hanging onto it . With actual revenues of 40-60 mill the last 5 quarters, one would think this stock price should rise. I wouldn’t mind seeing them bought out.
Classic sell the news. Probable offering coming next week to dilute on the good news.
Something just isnt right here. How do you get FDA approval for a drug and your stock price tank? Is there some bads news getting ready to come out on this company??
Something didn’t look good , I guess!
AKBA...FDA EXPLOSION ...WE LOADED THIS BEAUTY....KOCKED AND LOADED!!!!
AKBA...................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
AKBA.................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
$AKBA from stocktwits FDA’S THREE ALARM FIRE- (a)FDA issued CRL to FibroGen & Roxadustat (Aug. 2021); (b)FDA issued CRL to Akebia & Vadadustat (March 2022); (c)FDA’s Cardiovascular & Renal Drugs Advisory Committee supported GSK’s Daprodustat for dialysis dependent patients w/ anaemia of CKD w/ 13-3 vote (Oct. 2022); (d)Akebia submitted FDRR w/ FDA’s Senior Advisor in agency’s Office of New Drugs (OND) (Nov. 2022); (e)CKD community & key opinion leaders such as Dr. Jay Wish criticize FDA decision making concerning HIF-PHI drugs (March 2022 - present). (FDA knows from data that Daprodustat is inferior to Vadadustat.) FDA’S RESPONSE TO FIRE - (a)FDA met w/ Akebia to discuss appeal & subsequently requested “additional clarifying information” (not ADCOM, not clinical trial, not denial) (Nov. 2022); (b)FDA assigned Dr. Peter Stein, M.D., Director of OND as deciding authority for appeal (Feb. 2023); (c)Dr. Stein provided Akebia/Vadadustat w/ clear path forward to approval (May 2023). GLTA
Followers
|
45
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
419
|
Created
|
04/17/15
|
Type
|
Free
|
Moderators |
We are a fully integrated biopharmaceutical company. Our team works to address complications of kidney disease. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat. Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science.
VAFSEO® (vadadustat)is approved for use in 34 countries. Vadadustat has not been approved by the U.S. Food & Drug Administration.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |